Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Zhou, Hang http://orcid.org/0000-0002-7694-6391
Kember, Rachel L.
Vickers Smith, Rachel http://orcid.org/0000-0002-7224-8916
Justice, Amy C. http://orcid.org/0000-0003-0139-5502
Damrauer, Scott
Tsao, Philip S.
Klarin, Derek http://orcid.org/0000-0002-4636-5780
Baras, Aris
Reid, Jeffrey http://orcid.org/0000-0001-8645-4713
Overton, John
Rader, Daniel J.
Cheng, Zhongshan
Tate, Janet P.
Becker, William C.
Concato, John
Xu, Ke
Polimanti, Renato
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Article History
Received: 19 December 2018
Accepted: 6 March 2019
First Online: 2 April 2019
Change Date: 3 September 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Change Date: 17 May 2019
Change Type: Correction
Change Details: The original version of this Article omitted the following from the Acknowledgements: ‘Supported by the Mental Illness Research, Education and Clinical Center of the Veterans Integrated Service Network 4 of the Department of Veterans Affairs.’ This has now been corrected in both the PDF and HTML versions of the Article.
Competing interests
: H.R.K. is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which in the past three years was supported by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed 24 January 2018. The remaining authors declare no competing interests.